Evozyne

Chicago, United States

Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.

$81.0M raised

Sep 2023

Series B

Top Investors

Valor Equity PartnersOrbiMedFidelityParagon BiosciencesNVentures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Evozyne raised?

Evozyne has raised $81.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.

Who are Evozyne's investors?

Evozyne's investors include Valor Equity Partners, OrbiMed, Fidelity, Paragon Biosciences, NVentures.

Where is Evozyne headquartered?

Evozyne is headquartered in Chicago, United States.

What does Evozyne do?

Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.

What stage is Evozyne at?

Evozyne is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 27, 2023.

MLA

"Evozyne — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/evozyne. Accessed June 4, 2026.

APA

VCBacked. (2023). Evozyne — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/evozyne

Wikipedia (cite web)

{{cite web |title=Evozyne — Funding & Investors |url=https://www.vcbacked.co/company/evozyne |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 27, 2023.